Filing Flows › Myriad Genetics (MYGN) › Q2 2026 › vs Q1 2026
Myriad Genetics (MYGN) Q2 2026 vs Q1 2026 (quarter over quarter)
Myriad Genetics's revenue fell $9.7M (-5%) from $200M in Q1 2026 to $191M in Q2 2026. The biggest changes: Cancer Care Continuum −$6.1M (-5%); Prenatal Health −$2.1M (-5%); Mental Health −$1.5M (-4%).
Myriad Genetics, Q2 2026: revenue $191M (-10% year over year), operating margin -20.4%, net loss $43.2M, operating cash flow −$8.3M. The chart draws each line against Q1 2026, the increases inside each band.
Every line
| Line | Q2 2026 | Q1 2026 | Change | % |
|---|---|---|---|---|
| Cancer Care Continuum | $114M | $120M | −$6.1M | -5% |
| Prenatal Health | $39.8M | $41.9M | −$2.1M | -5% |
| Mental Health | $36.8M | $38.3M | −$1.5M | -4% |
| Revenue | $191M | $200M | −$9.7M | -5% |
| Net loss | $43.2M | $34.1M | $9.1M | +27% |
| Costs & expenses | $234M | $234M | −$600K | -0.3% |
| Operating costs | $230M | $231M | −$1.5M | -0.6% |
| Interest & other, net | $3.7M | $3.4M | $300K | +9% |
| Income tax | $600K | $0 | $600K | — |
| Cost of revenue | $63.7M | $62.8M | $900K | +1% |
| Research & development | $25.0M | $27.1M | −$2.1M | -8% |
| Sales & marketing | $83.1M | $73.6M | $9.5M | +13% |
| General & admin | $57.8M | $62.2M | −$4.4M | -7% |
| Operating cash sources | $43.2M | $34.1M | $9.1M | +27% |
| Depreciation & amortization | $12.5M | $12.5M | $0 | 0% |
| Share-based compensation | $7.2M | $6.5M | $700K | +11% |
| Working capital & other | $15.2M | −$600K | $15.8M | — |
| Cash used in operations | $8.3M | $15.7M | −$7.4M | -47% |
| Net loss absorbed | $43.2M | $34.1M | $9.1M | +27% |
Questions
How much did Myriad Genetics's revenue grow quarter over quarter in Q2 2026?
Myriad Genetics's revenue fell $9.7M (-5%) from $200M in Q1 2026 to $191M in Q2 2026.
What drove Myriad Genetics's revenue change in Q2 2026?
Cancer Care Continuum −$6.1M (-5%); Prenatal Health −$2.1M (-5%); Mental Health −$1.5M (-4%).